• About Us
  • Corporate Profile
  • Management Team
  • Board of Directors
  • Scientific Advisory Board
  • Respiratory and Acute Care Advisory Board
  • Cardiovascular Advisory Board
  • Immunology Advisory Board
  • Investors
• Products
• Research
  • sPLA2 - What is it?
  • Respiratory and Acute Care Program
  • sPLA2 in SCD
  • IMPACTS Trial Site
  • Scientific Advisory Board
  • Cardiovascular Program
  • sPLA2 in CVD
  • FRANCIS Trial Site
  • PLASMA Trial Site
  • PLASMA 2 Trial Site
  • Scientific Advisory Board
  • Immunology Program
  • A-623 in SLE and Autoimmune Diseases
  • Scientific Advisory Board
  • Preclinical Programs
  • Glossary
  • References
• News & Media
• Careers
• Contact Us

<< Return to Board of Directors

David E. Thompson‚ Director

David E. Thompson‚ now retired‚ was named vice president of corporate strategy business development‚ the ventures group‚ and alliance management for Eli Lilly and Company in January 2001. Prior to that‚ Mr. Thompson served as vice president of corporate business development for Eli Lilly and Company. Mr. Thompson joined Eli Lilly in 1971‚ and throughout the 1970s‚ held numerous positions in sales‚ marketing research‚ sales management‚ and new product planning and licensing. He was named president and general manager of Eli Lilly Canada‚ a Lilly affiliate‚ in November 1985 and president/CEO of IVAC Corporation‚ a medical device subsidiary in December 1986. He served as vice president of pharmaceutical product management and licensing from 1988–1992. Born in Lansing‚ Michigan‚ he received Bachelor of Science (BS) and Master of Business Administration (MBA) degrees from Michigan State University. Mr. Thompson retired from Eli Lilly and Company in July 2005 and currently serves as a member of the Board of Directors for a select group of pharmaceutical companies including Bayhill Therapeutics‚ Inc. and Anthera Pharmaceuticals.